Radiotherapy, Temozolomide, and Bevacizumab Followed by Irinotecan, Temozolomide and Bevacizumab in Newly Diagnosed Glioblastoma Multiforme: Preliminary Results from an Ongoing Phase II Trial
Publication
, Conference
Kirkpatrick, JP; Desjardins, A; Reardon, DA; Vredenburgh, JJ
Published in: International Journal of Radiation Oncology*Biology*Physics
September 2008
Duke Scholars
Published In
International Journal of Radiation Oncology*Biology*Physics
DOI
ISSN
0360-3016
Publication Date
September 2008
Volume
72
Issue
1
Start / End Page
S209 / S209
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kirkpatrick, J. P., Desjardins, A., Reardon, D. A., & Vredenburgh, J. J. (2008). Radiotherapy, Temozolomide, and Bevacizumab Followed by Irinotecan, Temozolomide and Bevacizumab in Newly Diagnosed Glioblastoma Multiforme: Preliminary Results from an Ongoing Phase II Trial. In International Journal of Radiation Oncology*Biology*Physics (Vol. 72, pp. S209–S209). Elsevier BV. https://doi.org/10.1016/j.ijrobp.2008.06.1537
Kirkpatrick, J. P., A. Desjardins, D. A. Reardon, and J. J. Vredenburgh. “Radiotherapy, Temozolomide, and Bevacizumab Followed by Irinotecan, Temozolomide and Bevacizumab in Newly Diagnosed Glioblastoma Multiforme: Preliminary Results from an Ongoing Phase II Trial.” In International Journal of Radiation Oncology*Biology*Physics, 72:S209–S209. Elsevier BV, 2008. https://doi.org/10.1016/j.ijrobp.2008.06.1537.
Kirkpatrick JP, Desjardins A, Reardon DA, Vredenburgh JJ. Radiotherapy, Temozolomide, and Bevacizumab Followed by Irinotecan, Temozolomide and Bevacizumab in Newly Diagnosed Glioblastoma Multiforme: Preliminary Results from an Ongoing Phase II Trial. In: International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2008. p. S209–S209.
Kirkpatrick, J. P., et al. “Radiotherapy, Temozolomide, and Bevacizumab Followed by Irinotecan, Temozolomide and Bevacizumab in Newly Diagnosed Glioblastoma Multiforme: Preliminary Results from an Ongoing Phase II Trial.” International Journal of Radiation Oncology*Biology*Physics, vol. 72, no. 1, Elsevier BV, 2008, pp. S209–S209. Crossref, doi:10.1016/j.ijrobp.2008.06.1537.
Kirkpatrick JP, Desjardins A, Reardon DA, Vredenburgh JJ. Radiotherapy, Temozolomide, and Bevacizumab Followed by Irinotecan, Temozolomide and Bevacizumab in Newly Diagnosed Glioblastoma Multiforme: Preliminary Results from an Ongoing Phase II Trial. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2008. p. S209–S209.
Published In
International Journal of Radiation Oncology*Biology*Physics
DOI
ISSN
0360-3016
Publication Date
September 2008
Volume
72
Issue
1
Start / End Page
S209 / S209
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences